Introduction {#s1}
============

Natural Killer (NK) cells are innate lymphoid cells (ILC) with potent cytotoxic effector activity, due to their constitutive expression of perforin and granzyme and ready ability to produce high amounts of IFNγ and other proinflammatory cytokines. Their original definition of "born natural killers"(NK) was due to their "perforin-armed" resting condition. Their activity encompasses multiple defense activities including detection and disposal of virus-infected or transformed cells, early detection of pathogens via pathogen-associated molecular patterns (PAMPs) that are recognized by an array of innate receptors (e.g., TLRs), recruitment other cells involved in immune responses thanks to the early secretion of chemokines (IL-8, RANTES, MIP1a, MIP1b) and cytokines (GM-CSF, IL-6, IL-1) upon PAMP recognition. Subsequently, however, their involvement in the regulation of downstream responses was recognized with continuous coordination of and support to downstream adaptive immune responses through crosstalk with dendritic cells ([@B1], [@B2]) and with T cells ([@B3]--[@B5]). Over the last 10 years, it became clear that conventional NK cells are part of an extended family of ILC which includes three additional groups of innate cells having remarkable functional parallels with known helper T (Th) cell subsets ([@B6], [@B7]). Within this family, distinctive transcription factor expression and cytokine production characterizes conventional NK cells (Eomes, IFNγ) from group 1 ILC (T-bet, IFNγ), group 2 ILC (Gata3, IL-5/IL-13), and group 3 ILC (Rorc, IL17/IL-22). Several properties of conventional NK cells, and in particular transcription factor expression, clearly set them apart from other ILC subsets ([@B8], [@B9]), and has led to suggest a distinction between "helper" ILCs (ILC1s, ILC2s, and ILC3s) and "cytotoxic" ILCs (NK cells) that parallels the CD4+ Th cells vs. CD8+ CTL duality ([@B10]).

The predominant sites of the human body in which NK cells are found include secondary lymphoid organs, bone marrow, liver, lungs, and decidua while an overall minority of body NK cells (\<2%) circulates in peripheral blood where they represent 5--15% of blood lymphocytes. Contrary to adaptive T or B cells, their functional specificity does not include somatic rearrangements. Their wide array of activating receptors is germline encoded and delivers potent triggering signals upon recognition of distress ligands expressed by stressed healthy as well as infected or transformed cells ([@B11]). NK cell function is tightly regulated by a balance between activating stimuli delivered through activating molecules and inhibitory signals primarily by HLA class I-specific inhibitory receptors ([@B12]). Inhibitory signaling recognizes self and, in most instances, overrides routine minor activating distress in order to avoid self-destruction unless NK cell activity is needed to control overt cell infection or transformation ([@B13]).

Similar to other blood cells, NK cells are generated from hematopoietic stem cells (HSC) residing in the bone marrow. Following the first experimental evidence of the possibility to rescue mice from lethal irradiation, the bone marrow (BM) has been identified as the main source of HSC in the body with a first estimate of 1 in 10e4 BM spleen-colony forming cells ([@B14], [@B15]). HSC with the characteristics of self-renewal and multipotency, that are able to generate more differentiated precursors along the pathways toward production of erythrocytes, leucocytes and platelets, were indeed thereafter identified in BM ([@B16]--[@B18]), with a frequency of 1 in 10e5 BM cells ([@B16]). According to a strictly hierarchical "stem tree" view where all cells derive from a common ancestor, progressive steps of differentiation of HSC lead to the generation of progressively more oligopotent precursors toward all blood cell lineages. The classical model of hematopoiesis postulates that the earliest fate decision toward NK cells downstream of HSCs is represented by the divergence of lymphoid and myeloid lineages. Erythroid and megakaryocyte lineages branch off before the lymphoid--myeloid split. This step is followed by myeloid--lymphoid divergence in which common lymphoid progenitors (CLPs), and common myeloid progenitors are generated ([@B19]). Alternate possibilities of a less stringent stem-root developmental model have been pursued. Thus, there is considerable heterogeneity in reconstituting HSCs, with proof of a less defined hierarchical transition reflecting different propensities for lineage-fate decisions by distinct myeloid-, lymphoid- and platelet-biased HSCs ([@B20], [@B21]). The low level of agreement on some aspects of decisional fate of progeny development in humans is primarily due to different experimental settings. So far, studies have been heterogeneous with regard to different aspects that that include the use of either adult or fetal/newborn materials that may be inadequate for a coherent comparison of results, the different study settings comparing analysis of precursors at steady state vs. repopulation studies with a push toward tissue and body repopulation after transplantation, and finally the exclusive use of healthy donors with a lack of data derived from disease states, in which the developmental push toward differentiation and self-maintenance may more strongly reflect the influence of inflammatory signals and/or of peripheral need caused by accelerated cell turnover.

The purpose of this review is to briefly summarize the findings on classical NK cell precursors in the bone marrow and to recapitulate recent findings on alternate new precursor populations. Only a brief mention to ILC development will be provided, since this is out of the purpose of the present work and may be obtained elsewhere ([@B7], [@B22]).

NK Cell Development and Intermediates in the BM {#s2}
===============================================

After the first description of multipotent Lin^−^CD34+CD45RA+CD10+CD38+ progenitors in the BM generating *in vitro* T, B, NK, and Dendritic Cells ([@B23]), it became clear that the BM was the primary site of where NK cell precursors dwell and may generate NK cells ([@B24]). In fact, neither the thymus nor the spleen seemed to be essential for NK cell growth as shown by NK cell persistence and preserved function in their absence ([@B25]--[@B27]). The role of postnatal as compared to fetal liver in NK cell generation was unclear at the time and still requires further studies in future). Early views on NK cell development considered the BM as the main site for NK precursor growth from HSC and also the site where progressive NK cell development takes place ([@B24]).

Early work on BM precursors provided evidence that CD7 expression on CD34^+^CD45RA^+^ HPCs enriches for NK cell precursors ([@B28]). Also co-expression of CD10 on BM CD34^+^ HPCs identified a CLPs generating NK cells ([@B23]). These progenitors lacked erythroid, myeloid, and megakaryocytic potential but contained a broad B, T, and NK cell and DC differentiation potential, suggesting that this population might correspond to the human postnatal common lymphocyte precursor (CLP). It was also clear that CD34^+^CD7^−^ and CD34^+^10^−^ HPCs also could generate NK cells, albeit with lower efficiency and with more stringent contact requirement with stromal cells ([@B21], [@B23], [@B28], [@B29]). Subsequent studies revealed that CD10 expression on progenitors is associated with a strong bias toward B cell potential with minimal T or natural killer (NK) cell potential ([@B28], [@B30], [@B31]). Thus, the stepwise process of lymphoid differentiation from multipotent HSC to the earliest lymphoid-primed multipotent progenitor (LMPP) in BM was not characterized by the expression of CD10 ([@B23]), but rather of L-selectin (CD62L) expression on CD3-CD14-CD19-(henceforth Lin^−^) CD34^+^CD10^−^ progenitors ([@B28]). These progenitors were devoid of erythroid or myeloid clonogenic potential corresponding to LMPP and had the ability to seed SLT and thymus through the CD62L homing signal ([@B21], [@B32], [@B33]). In the same BM setting, CD7 expression alone did not define lymphoid commitment, as a Lin^−^CD34+CD38--CD7+ population that had been identified as a LMPP in umbilical cord blood (UCB) ([@B34]) was not detected, and low CD7 expression in CD34^+^Lin^−^CD38^+^CD10^−^ cells was insufficient to define lymphoid restriction as erythroid progenitors could also be detected ([@B28]). In UCB, circulating CD34+CD45+CD7+CD10-- precursors could generate cells of the three lymphoid lineages, however, with a skewed potential toward the T/natural killer (T/NK) lineages. In contrast, CD34(^+^)CD45RA(^hi^)Lin(^−^)CD10(^+^) HPCs predominantly exhibited a B-cell differentiation potential. Also, a culture of purified CD34+ derived from UCB (without further subset sorting) with SCF, FLT3, IL-7, and IL15 generates *in vitro* CD3^−^CD16^+^CD56^+^CD244^+^CD33^−^ myelomonocytes and highly immature CD3^−^CD16^+^CD56^+^CD244^+^CD33^−^ NK cells that are substantially devoid of cytotoxic activity and of IFNγ production, without growth of T cells or other lieages ([@B35]--[@B37]).

More recently, Renaux et al. provided evidence that Lin^−^CD34^+^CD38^+^CD123^−^CD45RA^+^CD7^+^CD10^+^CD127^−^ cells purified from BM or UCB represent the unipotent NK cell precursor devoid of potential toward other lymphoid lineages ([@B37], [@B38]). These precursors are also detected in adult tonsils and fetal tissues and are different from Lin^−^CD34^+^ CD38^+^CD123^−^CD45RA^+^CD7^+^CD10^−^CD127^+^ cells, which can undergo different fates including myeloid lineages, and also different from Lin^−^CD34^+^CD38^+^CD123^−^CD45RA^+^CD7^+^CD10^+^CD127^+^ cells that generated only lymphoid lineages (T, B, ILC, NK cells) ([@B38]). Thus, this confirms previous reports on the origin of ILC from CD34+ precursors il SLT or UCB ([@B39], [@B40]). ILC development still bears some areas of uncertainty with need of additional focus ([@B6], [@B7]). Indeed, CD127 expression has been shown to represent a requirement for the fate decision toward ILC development from upstream precursors, which still bear NK, T, and B cell potency ([@B38]), and is expressed on ILC but not on NK cells. However, it is transiently not expressed on early innale lymphoid progenitors (EILIP) in the BM ([@B7], [@B41], [@B42]) and is also lacking on the single-fate NKP, which is supposed to be downstream ILC developmental potency ([@B38]).

Overall, therefore, it is clear that the BM harbors, in addition to totipotent HSCs, more committed lymphoid precursors with the ability to generate NK cells, including LMPP, CLP, and single-cell NKP. Also, there are evidences that the developmental fates of NK cells and of "helper" ILCs are intertwined in general up to CD127 retention on CLP. The occurrence of a local NK cell development in BM is not disputed, however, at present is not quantified and poorly defined.

The concept that the BM could not be the predominant site of NK cell development developed after the first reports on secondary lymphoid tissue NK cell composition. Indeed, lymphnodes were harboring predominantly large numbers of CD56^bright^ NK cells adjacent to T-cell-rich areas ([@B43]). This led to experiments showing that NK cells with a CD56^dim^ phenotype developed from CD56^bright^ NK cells to take place in SLTs ([@B44]). Proof of this concept followed these observations and was substantiated by Freud et al. ([@B45]) with the description and characterization in lymphnodes of CD34+ CLP generating CD56^bright^ NK cells *in vitro* ([@B45]). Subsequent work confirmed the presence of CD34+ CLP in SLT and thymus, generating CD56^bright^ NK cells. Finally, MMLP and CLP have been recovered from PB and from UCB, and in general are believed to transit from BM through PB toward peripheral tissues for further development. These observations, therefore, supported the concept that the BM is the site where HSC are contained and is the origin of MLP and CSP, and that the vast majority of NK cells may be generated in peripheral tissues (e.g., SLT) as progenies from CLP traveling from the BM.

BM Organization of the HSC Microenvironment {#s3}
===========================================

All the so-far described BM NK cell precursor populations have been investigated according to the assumption of an uncharacterized anatomical organization, in which HSC reside in the BM within specialized microenvironments or niches. Animal studies have contributed a wealth of information on hematopoietic organization of the marrow microenvironment. Quiescent HSCs reside in perivascular niches, in which different cell types express or release factors that promote HSC maintenance ([@B46]). Quiescent HSCs in mice BM associate specifically with small arterioles that are preferentially found in endosteal BM ([@B47]). The production of CXCL12 by cells present in the perivascular region, including stromal cells, sinusoidal endothelial cells, and mesenchymal progenitors, has been shown to support HSC retention. Accordingly, CXCL12 deletion in mice results in constitutive HSC mobilization ([@B48]).

Thus, the organization of HSC in BM niches and their retention by CXCL12 raises the fundamental question of whether HSCs and restricted progenitors, including CLP or NKP, reside within distinct, specialized niches or whether they share a common niche. Using CXCL12 knock-in mice and conditional CXCL12 deletion, Ding and Morrison provided evidence that *Cxcl12* was primarily expressed by perivascular stromal cells and at lower levels by endothelial cells, osteoblasts, and some haematopoietic cells ([@B20]). Interestingly, deletion of *CXCL12* from endothelial cells depleted HSCs and certain restricted progenitors, but not myeloerythroid or lymphoid-committed progenitors, from perivascular stromal cells, while deletion of *CXCL12* from osteoblasts depleted certain early lymphoid progenitors, but not HSCs ([@B20]). Therefore, these findings provided evidence that different stem/progenitor cells occupy distinct cellular niches in BM. Accordingly, while HSCs reside in a perivascular niche, early lymphoid progenitors are localized in an endosteal niche ([Figure 1](#F1){ref-type="fig"}).

![NK cell hematopoiesis in health and during systemic inflammation. A section of Bone Marrow with a sinusoid is represented. Vascular Niche in pink, osteoblast niche representation in yellow. Blue cells represent CXCR4- lymphoid or erythroid cells passively released in the sinusoid. A spectrum of the phenotypes of so far characterized CD34+ NK cell precursors is represented with reported progenies and is indicated by citation numbers. **(A)** Diagram of the Stem Cell Niche and NK cell precursors in Healthy Adult Bone Marrow. Lymphoid cells and precursors exiting passively from sinusoids are indicated by dark blue arrows and constitute the pool of CD34+ cells circulating in peripheral blood. A yellow box defines their trajectory toward SLT (CD62L+CCR7+) and the prevailing phenotype of NK cells grown under standard conditions *in vitro*. **(B)** The Stem Cell Niche and CD34+ NK cell precursors in Adult Bone Marrow during chronic inflammation. During chronic inflammation, inflammatory cytokines and mediators determine a reduction/shutdown of CXCL12 signaling within the BM niches, with decreased retention ability of CXCR4+ HSC and CLP that otherwise populate the BM but do not circulate in PB. Red arrows show "inflammatory" or "emergency" CD34+ cells exting the BM. A different composition of CD34+ peripheral blood pool is accordingly shown during inflammatory conditions (HIV, HCV, COPD, Tuberculosis, PAPA). Travel trajectories of Lin^−^CD34^+^DNAM-1^bright^CXCR4^+^ cells toward peripheral tissues are shown as these CD34+ CLPa express CX3CR1+, CXCR1+, CXCR3+, in addition to SLT-homing receptors (CD62L+CCR7+).](fimmu-10-02045-g0001){#F1}

This particular organization leaves open the fundamental question of whether the observation of stem/progenitor cells in healthy, steady state conditions actually reflects the whole progenitor potential that is present in the BM and whether this may actually reflect which progenitors/cell types are released from the BM during inflammatory states. Remarkably, support for this question is provided by the observation that chronic inflammation is associated with bone remodeling including endosteal niches, as a result of cytokine-induced modulation of the cells responsible for MMP-9/CXCR4-dependent HSC retention ([@B49], [@B50]). In this regard, proinflammatory cytokines, that include TNFα and IL-1, have been shown to regulate CXCL12 expression, induce lymphocyte mobilization by suppressing CXCL12 retention signals in BM, and to promote the appearance of developing B cells in the spleen ([@B51]). Importantly, BM egress could be achieved in the absence of amoeboid migration toward BM exit sites. Accordingly, immature B cell egress from BM has been shown to rely on CXCR4 down-regulation. This passive mode of cell egress from BM also contributes significantly to the export of other hematopoietic cells, including granulocytes, monocytes, and NK cells, and is reminiscent of erythrocyte egress ([@B52]).

Inflammation-Associated Lin^−^CD34^+^DNAM-1^bright^CXCR4^+^ Cell Precursors {#s4}
===========================================================================

Taken together, all the mentioned evidences showing that HSC and CLPs in the BM occupy distinct niches, contribute to generate the concept that BM exit modality in different physiological or pathological conditions differ. Thus, in steady state conditions, mature NK cells and CLP would exit the BM following CXCR4 down-regulation. On the contrary, in the presence of inflammation or inflammatory cytokines, including TNFα, IL-1, and G-CSF, the production of CXCL12 is suppressed and would then allow exit from the BM of lymphocytes lacking CXCR4 down-modulation.

Therefore, the question is whether any "inflammatory" CLP exist, and if so, is the progeny actually superimposable to the one of the so-far characterized CLPs described in BM and other tissues. According to this model and to the interplay between CXCL12 expression and inflammation, CLP and NK cell progenitors released from the BM following inflammatory conditions would be expected to still express CXCR4 ([@B20], [@B48], [@B50]--[@B52]).

Indeed, proof that "inflammatory" or "emergency" progenitors actually exist has been provided by the analysis of patients with chronic inflammatory disorders including patients with HIV-1, chronic HCV infection, TB, as well as COPD or PAPA syndrome ([@B53]).

During these inflammatory conditions, Lin^−^CD34^+^DNAM-1^bright^CXCR4^+^ cells can be detected in the PB, where they often represent the majority of CD34+ cells ([@B53]). These precursors were found to generate *in vitro* NK cells and T cells but not cells of myelomonocytic lineage under the assayed culture conditions, thus qualifying for a CLP definition. Lin^−^CD34^+^DNAM-1^bright^CXCR4^+^ CLP reside in the BM under steady-state conditions, where they represent 10% of CD34+ cells, while they are not or are poorly (\<0.5--1% of PBMC) detectable in PB in healthy, uninflamed conditions ([@B53]). The circulating pool size of Lin^−^CD34^+^DNAM-1^bright^CXCR4^+^ cells is significantly increased in patients with inflammatory disorders compared to HD. In cART-treated virologically suppressed HIV-1 patients, for instance, they may represent as much as 30% of Lin^−^ gated PBMC, and over one third of patients had proportions of circulating Lin^−^CD34^+^DNAM-1^bright^CXCR4^+^ cells in excess of 5% of PBMC ([@B53]). Notably, the proportion of circulating Lin^−^CD34^+^DNAM-1^bright^CXCR4^+^ correlated directly with fibrinogen concentrations and therefore different output from the BM to the PB likely reflect, among other factors, individual differences in systemic chronic inflammation ([@B53]).

In addition to high DNAM-1 and CXCR4 expression (which are absent on conventional CD34+ cells in PB or in UCMC), inflammatory or "emergency" CD34+ CLP express HLA-DR, CD38, CD69, while they do not express CD117, CD94, CD123, CD161. A fraction of these mobilized inflammatory CLP variably express no or very low CD7 (0.2--3%) or CD10 (0.2--10%). Therefore, these CLP represent a heterogeneous population that may well contain small proportions of more committed CD34+CD7+CD10+CD127-- single-lineage NK precursors similar to those described recently for classical CD34+ cells ([@B38]). These inflammation-dependent CLP, however, predominantly contain less committed precursors upstream the NK cell progenitor fate-decision, which have the potential do develop *in vitro* also to CD3+ T cells and to CD3+CD56+ cells. For example, according to the study by Doulatov et al. ([@B54]), Lin^−^CD34^+^DNAM-1^bright^CXCR4^+^ cells would surprisingly also fit in the group of megakaryocyte/erythroid precursors, characterized by the CD38+CD10--CD7--Flt3-- phenotype. In addition, their lack of CD127 and CD161 expression could rule out their developmental trajectory toward ILCs. This is confirmed by the lack of ILC growth *in vitro* and ILC-compatible transcription ([@B53]). However, there is still room for the possibility to find "inflammatory" ILC precursors, in view of the observation that EILIPs transiently lack CD127 ([@B7], [@B42]), and that so-far uncharacterized Lin^−^CD34^+^DNAM-1^bright^CXCR4^+^ precursors may be observed in infectious/inflammatory conditions.

Importantly, the chemokine receptor expression of Lin^−^CD34^+^DNAM-1^bright^CXCR4^+^ cells is different from the one of conventional circulating Lin^−^CD34^+^DNAM-1^−^CXCR4^−^ CLP. Indeed, while the latter predominantly express CD62L or CCR7 (\>90%) and therefore appear to be homing predominantly toward SLT, a relevant proportion (35%) of Lin^−^CD34^+^DNAM-1^bright^CXCR4^+^ cells express CXCR3, CXCR1, or CX3CR1 and therefore appear to be poised to a relevant extent to peripheral inflamed tissues, not only to SLT ([@B53]).

A peculiar feature of Lin^−^CD34^+^DNAM-1^bright^CXCR4^+^ cells is represented by the unusual characteristics of their NK and T cell progenies. Under limiting dilution conditions, NK cell progenies grow rapidly and, already 16--20 days after seeding, have acquired a mature NK cell phenotype with expression of Natural Cytotoxicity Receptors (NKp46, NKp30, NKp44), CD244, HLA-DR, NKG2D, DNAM-1, NKG2A/CD94, Killer-like Immunoglobulin Receptors (KIRs) ([@B53]). In addition, they express high levels of Perforin, are cytotoxic toward tumor cell lines, and produce abundant IFNγ. The NK cell progeny of Lin^−^CD34^+^DNAM-1^bright^CXCR4^+^ cells, produces IFNγ with an early production pattern ([@B53]), which is superimposable to the one observed in mature CD56^dim^ NK cells ([@B34], [@B53]). Since CD56^bright^ NK cells are known to be developmentally upstream of CD56^dim^ NK cells ([@B44], [@B55]) and have a "late" IFNγ production pattern ([@B34]), this IFNγ production pattern in the progenies is somehow surprising as one would rather expect a CD56^bright^-like pattern. In addition, this finding is also unusual as classical CD34+DNAM-1-CXCR4- cells generate CD56^bright^-like, poorly functional, maturing NK cells almost exclusively *in vitro*, that have low NCR and very low to absent perforin, NKG2D, DNAM-1 expression and IFNγ production ([@B31], [@B46]). Indeed, NK cells develop from CD34+ precursors following a 4-staged expression of receptors (CD34, CD117, CD94, CD56, CD16), originally described by Freud and coll in CD34+ cells from tonsils and lymph nodes ([@B55]), and more recently revised to include six distinct stages ([@B56]). In particular, a small fraction of maturing NK cell progenies from "classical" CD34+DNAM-1- precursors may express KIRs only after prolonged culture and IL-21 stimulation ([@B37]), while progenies from "inflammatory" Lin^−^CD34^+^DNAM-1^bright^CXCR4^+^ cells in the BM and PB readily express KIRs after 16--20 days of progenitor seeding, and may follow a different staged development ([@B53]).

Concluding Remarks {#s5}
==================

Thus, "inflammatory" DNAM-1^bright^ CD34^+^CXCR4^+^ CLP ([@B53]), distinct from "classical" CD34^+^DNAM-1^−^CXCR4^−^ progenitors ([@B23], [@B24], [@B38], [@B45], [@B55]--[@B57]), stably reside in BM at steady state in a presumed osteoblast niche. They do not circulate in PB in easily detectable amounts, but are ready to be rapidly deployed to the peripheral tissues following stimuli that may include inflammation-induced CXCL12 downmodulation ([@B48], [@B51], [@B52]) ([Figure 1B](#F1){ref-type="fig"}). Recruitment to the periphery includes, for example, G-CSF. Indeed, G-CSF-induced mobilization/harvest protocols for transplantation purposes where Lin^−^CD34^+^DNAM-1^bright^CXCR4^+^ cells are released together with other CD34+ HSC/CLPs ([@B53]). Importantly, Lin^−^CD34^+^DNAM-1^bright^CXCR4^+^ cell frequencies in PB prevail over conventional CD34^+^DNAM-1^−^CXCR4^−^ cells during chronic inflammation. This "emergency" deployment may be mechanistically interpreted to support the model of a CD34+ travel trajectory toward inflamed peripheral tissues---in addition to SLT---when an increased turnover of lymphoid cells occurs at sites of infection/inflammation. This would allow the prompt availability of function-ready NK cells with an unconventional mature CD56dim-like functional activity.

Thus, the current views of NK cell development need to take into account recent evidences. Indeed, our views have been upgraded from a strictly hierarchical stepwise organization of fate decisions for HSCs and CLPs toward progressively more restricted maturing potentials ([@B23], [@B38], [@B55], [@B56]) to a comprehensive system where HSC and CLP fate decisions are less strict. In this comprehensive system, they depend on more shared transcriptional programs, additional conditions including local tissue signals (e.g., delivered by stromal cells) and system requirements (steady state vs. recolonization) ([@B58]--[@B61]). Modeling in the presence of increased peripheral turnover with inflammation has so far been assumed to fall into the "steady state," and has therefore led to the substantial lack of consideration of "inflammatory" CD34+ in studies on NK cell development ([@B24], [@B54]--[@B56]). Thus, this explains how these CLPs eluded characterization for a long time. With the demonstration of the regulation of HSC release from distinct niches in the BM ([@B20], [@B46]--[@B48], [@B50]), and the characterization of "inflammatory" CD34+ progenitors in the BM ([@B53]), some so-far unanswered questions along the path of NK cell development could be addressed. Indeed, the surprisingly wide spectrum of NK cell phenotypic and functional repertoires ([@B62]) still has unanswered aspects, including the origin of tissue-resident NK cells, the origin of such a variety of phenotypic differences, and the exact boundaries for the generation of memory-like NK cells ([@B1], [@B63]--[@B69]). Inclusion of Lin^−^CD34^+^DNAM-1^bright^CXCR4^+^ in the modeling of NK cell development in inflamed BM, SLT and peripheral tissues introduces an additional level of complexity to an already full pattern of developmental steps ([@B56], [@B59]), but will help to address some unanswered questions. In view of the ongoing effort at redirecting NK cells for immunotherapeutic purposes (e.g., anti-KIR, anti-NKG2A mAbs, CAR-NK engineering), the existence of inflammatory CD34+DNAM-1^bright^ precursors with extremely functional NCR+NKG2D+ NK cells could represent a useful tool for immunotherapeutic purposes.
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